| Symposium held to seek new growth engines in the pharma/bio industry and provide opportunities for strategic collaboration
| Numerous companies and institutions related to innovative drug development attended, including LOTTE BIOLOGICS, KIMCo, and Kangwon National University Technology Holdings
| Private networking session saw major bio-ventures and institutional representatives engage in active collaboration discussions
| JNPMEDI Partners to strengthen its role as a bridge connecting institutions, corporations, and startups in the pharma/bio sector
JNPMEDI Partners (CEO Kwon-ho Jung), a global accelerator in the pharmaceutical and bio sectors, announced on the 17th that it has successfully concluded ‘JNPMEDI PARTNERS CONNECT 2025.’
Held at Gyeongwonjae Ambassador Seoul - Associated with Pullman in Songdo, Incheon, the event was designed under the theme of ‘Pharma/Bio Open Innovation and Partnerships’ to seek new growth engines within the industry and create opportunities for strategic collaboration.
The event was attended by numerous major companies and organizations supporting the innovative drug development ecosystem, including LOTTE BIOLOGICS, the Utah Industry and Economic Development Asia Office, Incheon Techno Park, the Gachon Advanced Institute for Health Sciences and Technology, the Incheon Center for Creative Economy & Innovation, the Inha University Hospital Open Laboratory, KIMCo (Korea Innovative Medicines Consortium), and Kangwon National University Technology Holdings.
The program consisted of two session presentations followed by a networking program, providing a platform for participants to exchange business and technical capabilities. In the first session, a lecture on ‘New Drug Development Cases and Trends Utilizing Open Innovation’ presented the direction for domestic and international bio collaboration models. The second session, themed ‘Establishing Value Chains through Open Innovation,’ emphasized the goals of open innovation and the necessity of creating innovative value.
The final networking session was conducted privately in conjunction with a luncheon. Ten investment professionals from eight CVCs and VCs joined representatives from major bio-ventures and institutions to engage in free discussions regarding business strategies, collaboration models, and investment opportunities.
Kwon-ho Jung, CEO of JNPMEDI Partners, stated, “This event is highly significant in that innovative companies and institutions within the Songdo Bio Cluster closely united to create a collaborative ecosystem for technology commercialization, clinical development, and global strategy based on an open innovation system.” He added, “We will do our best to support the growth of innovative companies with global competitiveness by serving as a bridge connecting institutions, corporations, and startups.”
| Symposium held to seek new growth engines in the pharma/bio industry and provide opportunities for strategic collaboration
| Numerous companies and institutions related to innovative drug development attended, including LOTTE BIOLOGICS, KIMCo, and Kangwon National University Technology Holdings
| Private networking session saw major bio-ventures and institutional representatives engage in active collaboration discussions
| JNPMEDI Partners to strengthen its role as a bridge connecting institutions, corporations, and startups in the pharma/bio sector
JNPMEDI Partners (CEO Kwon-ho Jung), a global accelerator in the pharmaceutical and bio sectors, announced on the 17th that it has successfully concluded ‘JNPMEDI PARTNERS CONNECT 2025.’
Held at Gyeongwonjae Ambassador Seoul - Associated with Pullman in Songdo, Incheon, the event was designed under the theme of ‘Pharma/Bio Open Innovation and Partnerships’ to seek new growth engines within the industry and create opportunities for strategic collaboration.
The event was attended by numerous major companies and organizations supporting the innovative drug development ecosystem, including LOTTE BIOLOGICS, the Utah Industry and Economic Development Asia Office, Incheon Techno Park, the Gachon Advanced Institute for Health Sciences and Technology, the Incheon Center for Creative Economy & Innovation, the Inha University Hospital Open Laboratory, KIMCo (Korea Innovative Medicines Consortium), and Kangwon National University Technology Holdings.
The program consisted of two session presentations followed by a networking program, providing a platform for participants to exchange business and technical capabilities. In the first session, a lecture on ‘New Drug Development Cases and Trends Utilizing Open Innovation’ presented the direction for domestic and international bio collaboration models. The second session, themed ‘Establishing Value Chains through Open Innovation,’ emphasized the goals of open innovation and the necessity of creating innovative value.
The final networking session was conducted privately in conjunction with a luncheon. Ten investment professionals from eight CVCs and VCs joined representatives from major bio-ventures and institutions to engage in free discussions regarding business strategies, collaboration models, and investment opportunities.
Kwon-ho Jung, CEO of JNPMEDI Partners, stated, “This event is highly significant in that innovative companies and institutions within the Songdo Bio Cluster closely united to create a collaborative ecosystem for technology commercialization, clinical development, and global strategy based on an open innovation system.” He added, “We will do our best to support the growth of innovative companies with global competitiveness by serving as a bridge connecting institutions, corporations, and startups.”